Mg Magnesium Sulphate Heptahydrate Inresa

Magnesium sulfate heptahydrate, the active ingredient in Mg Magnesium Sulphate Heptahydrate Inresa, is a magnesium salt presented as a sterile solution for intramuscular and intravenous use. It restores extracellular magnesium levels and is employed in the management of magnesium deficiency and related acute conditions in hospital settings.

GNH USA supplies Mg Magnesium Sulphate Heptahydrate Inresa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Magnesium sulfate heptahydrate is used to correct magnesium deficits and to manage acute conditions where magnesium’s physiological actions are therapeutic. - Magnesium deficiency: restores normal extracellular magnesium concentrations and alleviates related neuromuscular symptoms. - Eclampsia and preeclampsia: prevents seizures by stabilising neuronal excitability in pregnant patients. - Torsades de pointes: shortens QT interval and reduces ventricular arrhythmia risk. - Severe asthma exacerbations: relaxes bronchial smooth muscle to improve airflow. - Constipation: increases intestinal water content and promotes motility.

Adverse reactions may vary with dose, route, and patient condition.

Common Side Effects: - Flushing or warmth at the injection site - Nausea or vomiting - Headache - Dizziness or light‑headedness - Sweating - Mild hypotension

Serious or Rare Side Effects: - Severe hypotension or cardiovascular collapse - Cardiac arrhythmias including bradycardia - Respiratory depression - Hypermagnesemia with neuromuscular weakness - Anaphylactic reaction - Cardiac arrest

Magnesium sulfate should be administered with attention to patient‑specific risk factors and monitoring requirements. - Renal impairment: adjust dose or avoid if severe, as clearance is reduced. - Cardiac conduction disorders: monitor ECG for bradyarrhythmias. - Neuromuscular disease: watch for exaggerated muscle weakness. - Electrolyte imbalance: correct concurrent calcium or potassium abnormalities. - Pregnancy and lactation: use only if clearly indicated, benefits outweigh potential risks. - Store at ambient temperature: keep in original container, protect from light and moisture.

Magnesium sulfate can alter the activity of several co‑administered medicines.

Major Interactions (Avoid): - Calcium channel blockers: additive vasodilatory effect may cause severe hypotension. - Neuromuscular blocking agents: potentiation can lead to prolonged paralysis. - Other magnesium‑containing products: risk of hypermagnesemia.

Moderate Interactions (Monitor Closely): - Aminoglycoside antibiotics: increased risk of neuromuscular blockade. - Loop diuretics: may enhance magnesium loss, requiring monitoring. - ACE inhibitors or ARBs: monitor blood pressure and renal function. - NSAIDs: may affect renal clearance of magnesium. - Antacids containing aluminum or magnesium: assess total magnesium load.